Related Experiment Video
Updated: Jun 5, 2026
Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients
Yayoi Shiotsu1, Yasukiyo Mori, Masato Nishimura
1Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto 608-8566, Japan.
Insights
Plasma S100A12 protein levels are significantly higher in hemodialysis patients with cardiovascular disease. Elevated S100A12 is an independent predictor of cardiovascular disease prevalence in this high-risk population.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Cardiovascular disease (CVD) is a leading cause of death in patients with chronic kidney disease (CKD) undergoing hemodialysis.
- S100A12 protein, an endogenous ligand for advanced glycation end products, has emerged as a potential biomarker in inflammatory conditions.
Purpose of the Study:
- To investigate the association between plasma S100A12 protein levels and the prevalence of cardiovascular disease in maintenance hemodialysis patients.
Main Methods:
- A cross-sectional study involving 550 hemodialysis patients.
- Assessment of past cardiovascular disease history and quantification of plasma S100A12 protein levels.
Main Results:
- Hemodialysis patients with cardiovascular disease exhibited significantly higher plasma S100A12 levels compared to those without (33.8 ± 28.1 ng/ml vs. 20.2 ± 16.1 ng/ml, P<0.001).
- Plasma S100A12 level was an independent predictor of cardiovascular disease prevalence (OR, 1.28; 95% CI, 1.13 to 1.44; P<0.001), alongside diabetes mellitus and hs-CRP.
- A significant association persisted even in hemodialysis patients without diabetes (OR, 1.30; 95% CI, 1.09 to 1.54; P=0.004).
Conclusions:
- Plasma S100A12 protein level is strongly associated with the prevalence of cardiovascular disease in hemodialysis patients.
- S100A12 may serve as a valuable biomarker for cardiovascular risk stratification in CKD patients on hemodialysis.
Background And Objectives:
S100A12 is an endogenous receptor ligand for advanced glycation end products. Cardiovascular disease remains a major cause of morbidity and mortality in patients with chronic kidney disease. In this study, we report cross-sectional data on 550 hemodialysis patients and assess the relationship between plasma S100A12 level and cardiovascular disease.
Design, Setting, Participants, & Measurements:
A cross-sectional study of 550 maintenance hemodialysis patients was conducted. We investigated the past history of cardiovascular disease and quantified the plasma level of S100A12 protein in all participants.
Results:
Plasma S100A12 level was higher in hemodialysis patients with cardiovascular disease (n=197; 33.8 ± 28.1 ng/ml) than in those without it (n=353; 20.2 ± 16.1 ng/ml; P<0.001). In multivariate logistic regression analysis, the plasma S100A12 level (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.13 to 1.44; P<0.001) was identified as an independent factor associated with the prevalence of cardiovascular disease. The other factors associated with the prevalence of cardiovascular diseases were the presence of diabetes mellitus (OR, 2.81; 95% CI, 1.79 to 4.41; P < 0.001) and high-sensitivity CRP level (OR, 1.02; 95% CI, 1.00 to 1.05; P=0.046). Furthermore, the plasma S100A12 level (OR, 1.30; 95% CI, 1.09 to 1.54; P=0.004) was significantly associated with cardiovascular disease even in hemodialysis patients without diabetes mellitus (n=348).
Conclusions:
These results suggest that the plasma S100A12 protein level is strongly associated with the prevalence of cardiovascular disease in hemodialysis patients.
Related Concept Videos
01:24Hemodialysis II: Procedure and Complications
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:25Hemodialysis I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Hemodialysis III: Nursing Management
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...